Format

Send to

Choose Destination
See comment in PubMed Commons below
Nat Rev Drug Discov. 2008 Nov;7(11):909-25. doi: 10.1038/nrd2358.

Novel therapeutic strategies for multiple sclerosis--a multifaceted adversary.

Author information

1
Department of Neurology, Harvard Medical School, Brigham and Women's Hospital, Harvard Institute of Medicine Room 730, 77 Avenue Louis Pasteur, Boston, Massachusetts 02115, USA.

Abstract

Therapeutic strategies for multiple sclerosis have radically changed in the past 15 years. Five regulatory-approved immunomodulatory agents are reasonably effective in the treatment of relapsing-remitting multiple sclerosis, and appear to delay the time to progression to disabling stages. Inhibiting disease progression remains the central challenge for the development of improved therapies. As understanding of the immunopathogenesis of multiple sclerosis has advanced, a number of novel potential therapeutics have been identified, and are discussed here. It has also become apparent that traditional views of multiple sclerosis simply as a CD4+ T-cell-mediated disease of the central nervous system are incomplete. The pathogenic role of other immune components such as the innate immune system, regulatory T cells, T helper 17 cells and B cells is reaching centre stage, opening up exciting avenues and novel potential targets to affect the natural course of multiple sclerosis.

PMID:
18974749
DOI:
10.1038/nrd2358
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Support Center